The active cell immunotherapy preparation DCVAC/LuCa developed by biotechnology company SOTIO of the group PPF reduces, in combination with a chemo-therapy, the risk of death of patients in the stage IV of the non small cell lung carcinoma by 46%. This stems from a clinical study of the stage I/II adding that patients with the dosage of the drug DCVAC/LuCa showed the total survival of 15.5 month compared with 11.8 month recorded in the control group with a standard treatment. The DCVAC/LuCa therapy showed no significant side effects. SOTIO is considering the launch of further clinical studies of stages II or III.
Source: CIA News
Provided by team CzechTrade Seoul